When do biologic drug patents expire and when will biosimilars launch?

United States Patent 10,280,230: What Do the Claims Actually Cover, and Where Does the Landscape Stand?

United States Patent 10,280,230 is a method and product-by-process patent centered on glycoengineering in “immortalized human blood” host cells to produce protein/glycoprotein compositions with a defined combination of glycosylation traits. The independent claim strategy relies on (1) selecting a particular host cell class identified by functional glycan readouts and (2) driving expression of a target protein via a DHFR-based antifolate selection system (claims 8 and 9). The claims then broaden the scope across protein modalities and antibody families using expansive genus language, while anchoring enforceability to the defined glyco-trait thresholds versus benchmark cell lines CHOdhfr- [ATCC CRL-9096], and in places vs NM-F9 [DSM ACC2606] and NM-D4 [DSM ACC2605].

This landscape analysis focuses on claim scope mechanics, likely novelty points (where infringement and validity disputes will concentrate), and the competitive patent territory around human cell glycoengineering, sialylation, fucose suppression, and antifolate-resistant DHFR expression systems.

What Is the Core Claimed Invention? (Claim Architecture and Claim-Limiting Features)

1) Independent claim 1: the functional host-cell selection gate

Claim 1 requires a method for producing a “protein molecule composition” with glycosylation outcomes defined at the carbohydrate-structure level and linked specifically to sialylation (NeuNAc, α2-6 linkages) and absence of immunogenic/targeted glycans (NeuGc and terminal Galα1-3Gal) in dependent claims. The decisive novelty is not the culture step itself but the selection of a specific “immortalized human blood host cell” that meets glycan performance metrics.

Claim 1 elements (condensed):

(a) Selecting an immortalized human blood host cell that produces a protein composition with:
- (i) no detectable NeuGc
- (ii) α2-6 linked NeuNAc
- (iii) increased sialylation degree:
- amount of NeuNAc on total carbohydrate structures or at a specified glycosylation site
- ≥ 15% higher versus the same protein expressed in CHOdhfr- [ATCC CRL-9096]
(b) Introducing nucleic acid encoding at least part of said protein
(c) Culturing under conditions permitting production
(d) Isolating the protein composition

Critical limiting features

Enforceability is tightly coupled to the host cell selection criteria (NeuGc negative; α2-6 NeuNAc positive; ≥15% sialylation uplift versus CHOdhfr-).
The comparison standard is not “global sialylation” in isolation; it is NeuNAc quantity relative to CHOdhfr- for the same protein, in expressed form.

2) Dependent claims expand glycan phenotype and benchmarking

Claim 2 adds alternate or additional host-cell selection options:
- no detectable terminal Galα1-3Gal
- bisecting GlcNAc at ≥2% or ≥5%
- stronger sialylation at ≥20% uplift vs CHOdhfr-
- fucose-lacking at ≥50% carbohydrate structures lacking fucose
- sialylation higher than in NM-F9 (DSM ACC2606) or NM-D4 (DSM ACC2605), with the note that NM-F9/NM-D4 only reach ~50–60% of the achieved sialylation
Claim 3 pivots to galactosylation and related glyco-structure distribution:
- increased galactosylation degree
- G2 increase ≥5%
- G0 decrease ≥5%
- fucose decrease ≥5%
- altered sialylation pattern compared to CHOdhfr- for the same protein
Claim 5 imposes additional combinational thresholds (some conjunctive, some disjunctive language):
- carbohydrate structures ≥10% lacking fucose
- and/or ≥5% bisecting GlcNAc-containing structures
- and/or >35% G2
- and/or <22% G0

3) Claim 6 ties glycosylation phenotype to performance outcomes

Claim 6 claims that the produced composition has one or more functional advantages relative to CHOdhfr- expressed comparators:

increased activity and/or increased yield
improved homogeneity, including glycosylation homogeneity
yield up ≥10%
antibody outcomes:
- Fc-mediated cellular cytotoxicity ≥2x
- binding (antigen-mediated or Fc-mediated) ≥15% higher

This is a classic validation bottleneck: if a competitor can match the glyco-phenotype but does not observe the functional delta, enforceability may still hinge on whether the dependent claim requires the performance metric as a claim limitation or merely describes consequences. Here, the claim language reads as a limitation tied to the produced composition.

4) Claim 8 and 9: antifolate-resistant DHFR variant and methotrexate selection

Claim 8 requires that the introduced nucleic acid encodes an antifolate resistant DHFR variant and the host is cultured with an antifolate.
Claim 9 identifies antifolate as methotrexate and constrains DHFR variant sequences to SEQ ID 1 to 9.

This positions the invention as a specific expression system rather than a generic “human cell expression” concept.

5) Claims 10–12 and 13–15: broad protein and antibody genus mapping

The specification-level breadth is expressed via method claim lists:

Claim 10 lists proteins spanning cytokines, growth factors, clotting factors, albumin, VEGF, etc., plus “antibodies, immunoadhesins, and MUC1.”
Claims 11–15 define antibody is a fragment or selected from many marketed mAbs and related constructs (Pankomab and a long list including rituximab, trastuzumab, cetuximab, etc.).

6) Claims 7 and 36: host cell subtype focus

Claim 7 states host cells selected from:
- higher sialylation than K562
- low/no fucosylation
- human myeloid leukemia origin
- derived from K562
- selected specific immortalized lines:
- NM-H9D8 [DSM ACC2806]
- NM-H9D8-E6 [DSM ACC2807]
- NM-H9D8-E6Q12 [DSM ACC2856]
Claim 36 restates these in an “isolated cell” format.

7) Claim 34: product claim for the immortalized cell

Claim 34 claims an immortalized human blood cell capable of producing compositions meeting glycosylation characteristics, again anchored to:

no detectable NeuGc
α2-6 linked NeuNAc
sialylation degree ≥15% higher vs CHOdhfr-
≥2% bisecting GlcNAc-containing structures

Claim 35 and 37 further expand cell phenotype and nucleic acid encoding constraints.

Bottom line: The patent is best understood as a host-cell-centered glycoengineered platform plus a DHFR/methotrexate expression system, with performance assertions that become enforceability-critical in dependent claim posture.

What Makes These Claims Potentially Novel (and Where the Validity Attack Will Land)?

1) The combination constraint is the novelty anchor

A validity challenge will likely argue lack of novelty or obviousness by combining known elements:

human cell expression for therapeutic proteins
glycoengineering to reduce NeuGc and terminal Galα1-3Gal
α2-6 sialylation promotion
fucose suppression and bisecting GlcNAc pathways
DHFR/methotrexate selection in CHO-like systems

The patent’s counter is that it claims a specific functional host cell class with quantitative glyco readouts against specific comparator cell lines. That combination is harder to map from earlier art if earlier references do not report those exact benchmark deltas.

2) Benchmarking against CHOdhfr- is a common litigation pressure point

Because claim thresholds are written as percent deltas vs CHOdhfr- [ATCC CRL-9096], prior art must:

demonstrate comparable glycosylation uplift against a “same protein expressed in CHOdhfr-” comparator, or
show that the claimed glyco traits were already achieved with known alternatives such that an expert would find it obvious to select the human host cell you claimed.

From a validity standpoint, the most damaging prior art would provide:

a human immortalized cell line with NeuGc-negative, α2-6 NeuNAc high profile
and a route to DHFR-based selection
and quantitative glycosylation metrics.

3) Performance-dependent dependent claims can be attacked as non-limiting or non-proving

Claim 6 includes activity/yield/homogeneity and antibody binding/cytotoxicity thresholds. An attack strategy can argue:

glyco traits do not necessarily correlate to those functional thresholds for all proteins
the patent may overpromise beyond what depends from glycan composition alone.

From the claim text alone, the patent ties functional outcomes to “the produced composition,” meaning applicants likely supported those correlations empirically. In enforcement, defendants typically pursue both claim construction and experimental irreproducibility.

Where Could Competitors Design Around? (Practical Design-Around Angles)

1) Break the host-cell selection gate

Because claims 1/34 require selecting an immortalized human blood host cell with explicit glycan characteristics, a competitor can target:

a non-blood human cell lineage (even if immortalized)
a human line that still suppresses NeuGc and improves α2-6 sialylation but does not achieve the ≥15% NeuNAc uplift vs CHOdhfr-
a line that is NeuNAc-positive but has different linkage distribution (α2-6 not achieved)

2) Keep the glyco phenotype but remove the DHFR/methotrexate constraint

Claims 1 and many dependent claims do not require DHFR/methotrexate. But claims 8 and 9 do. Competitors can use alternative expression enhancement systems (non-DHFR, transient systems, different selectable markers) to avoid those dependent claims. In infringement practice, that is often enough to strip asserted claim scope to the narrower independent claim set.

3) Meet the “no NeuGc” and “α2-6 NeuNAc” traits but not the quantitative thresholds

Because multiple dependent claims are written in percent ranges (≥2%, ≥5%, ≥20% uplift, ≥50% lacking fucose, >35% G2, <22% G0), design-around can focus on:

staying close to thresholds but not crossing them
shifting the glycan distribution from G2 heavy to another distribution while preserving sialylation.

4) For antibodies: change Fc engineering so the functional performance is different

Claim 6 adds functional antibody endpoints (cytotoxicity and binding deltas). If competitors alter Fc sequences or introduce Fc region variants, they may preserve glyco traits but avoid functional performance limitations tied to a “same antibody expressed in CHOdhfr-” comparator.

Patent Landscape: What Territory Are You Actually Buying?

Because the user provided only claim text (not the full patent bibliographic record, prosecution history, or cited references), the analysis of the external landscape can only be anchored to the claim-defined benchmark cell lines and the generic claim categories visible in the text.

A. Benchmark comparator cell lines define the competitive reference frame

The claims repeatedly reference:

CHOdhfr- [ATCC CRL-9096] as baseline
NM-F9 [DSM ACC2606] and NM-D4 [DSM ACC2605] as intermediate benchmark for sialylation

Competitive systems likely cluster around glycoengineered performance in CHO and alternative mammalian platforms. The patent tries to exclude generic “human expression” by tying glyco traits to these precise comparators.

B. The host-cell origin term is a narrowing lens

“Immortalized human blood cell” and related descriptors (K562 derivatives; human myeloid leukemia origin) likely narrow the platform. The inclusion of specific DSM line IDs in claims 7 and 36 suggests the assignee has cell bank identifiers that can be used to prove possession or infringement by cell sourcing and characterization.

C. Glycan phenotype claim set overlaps known industry targets

Even without external citation, the claim phenotype is aligned to common therapeutic glycan goals:

reduce NeuGc (immunogenicity)
reduce terminal Galα1-3Gal (xenoantigen)
boost α2-6 sialylation
increase bisecting GlcNAc
reduce fucose (often linked to increased antibody ADCC)
shift G0/G2 distribution toward more complex structures and higher galactosylation

This is important for the landscape: you are not protecting “sialylation” in the abstract. You are protecting a particular host-cell platform that delivers a particular quantified pattern.

D. Expression system claim elements add a second moat

The DHFR/methotrexate antifolate resistant selection in claims 8 and 9 is another layer. Competitors who use alternative selection systems (or stable lines not created with DHFR selection) may still infringe the independent claim if their host cells meet the glycan selection gate, but they can avoid dependent claim coverage tied to DHFR variant sequences in SEQ ID 1 to 9.

Claim-by-Claim Enforcement Map (Where Litigation Will Focus)

Claim	Core limitation type	Highest litigation leverage	Likely design-around leverage
1	Host-cell selection by glycan phenotype + ≥15% NeuNAc uplift vs CHOdhfr-	Very high (independent gate)	Medium to high (miss threshold or host definition)
2	Additional glycan phenotype options (Galα1-3Gal, bisecting GlcNAc %, fucose-lacking, NM-F9/D4 benchmark)	High	High (stay below thresholds, change benchmark outcome)
3	Galactosylation and glyco structure distribution (G2 +5%, G0 -5%, fucose -5%)	High	High
4	Sialylation pattern via NeuNAc ≥20% uplift and/or ≥20% more charged sialylated chains	Medium	Medium
5	Conjunctive/disjunctive glycan distribution thresholds (fucose-lacking, bisecting GlcNAc, G2 >35%, G0 <22%)	Medium	Medium
6	Functional outcomes (yield, activity, homogeneity; antibody ADCC and binding deltas)	Medium to high (if pursued)	High (protein engineering, assay variation, comparator changes)
7	Host-cell selection group includes K562 origin and specific DSM lines	Medium	Medium (use non-covered lines/origins)
8	DHFR variant selection + antifolate culture	Medium	High (remove DHFR/methotrexate selection)
9	Methotrexate and SEQ ID 1–9 DHFR variants	Medium	High
10–12, 13–15	Broad protein and antibody genus mapping	Low to medium (depends on infringement of glyco gate)	Low to medium
34–36	Cell product claims for immortalized cell phenotype and specific DSM lines	Medium (proof burden shifts to characterization)	Medium
37	Cell nucleic acid constraints including SEQ ID 1–9	Medium	High

Strategic Implications for R&D and Investment Decisions

1) The patent is a platform claim more than a single-protein claim

Even though claims list proteins and antibodies, enforceability will concentrate on:

cell line identity/characterization
glycosylation quantification assays
comparison methodology versus the stated CHOdhfr- comparator.

A protein-specific commercial plan is less decisive than the platform’s ability to hit the claim glyco metrics.

2) The DHFR selection component expands prosecution-grade defensibility

Claim 8 and 9 restrict antifolate selection to methotrexate and SEQ ID 1–9 DHFR variants. That can reduce the set of obvious combinations and helps establish that the assignee claimed more than generic stable expression.

3) The performance claims create a secondary proof burden

If the assignee asserts claim 6 dependently, the defendant’s best lever is often:

assay methodology differences
protein-specific variation
different comparator and expression controls.

That is a practical litigation lever for competitors.

Key Takeaways

US 10,280,230 is anchored to a functional host-cell selection gate: NeuGc-negative, α2-6 NeuNAc positive, with ≥15% NeuNAc uplift vs CHOdhfr- [ATCC CRL-9096] (claim 1).
The dependent claim set builds an enforcement grid around quantified glycan distribution (bisecting GlcNAc, fucose-lacking, G2/G0 shifts) and additional benchmarking versus NM-F9 [DSM ACC2606] and NM-D4 [DSM ACC2605] (claims 2–5).
Claims 8–9 add a mechanistic moat around methotrexate selection using a DHFR variant limited to SEQ ID 1–9.
The broad protein and antibody genus language (claims 10–15) matters commercially, but infringement still turns on meeting the host-cell glyco thresholds.
The highest design-around leverage is host-cell selection criteria and crossing (or not crossing) the quantitative glyco thresholds, with an additional escape from dependent claim coverage by avoiding DHFR/methotrexate + specific SEQ ID DHFR variants.

FAQs

1) What is the single most important claim limitation in US 10,280,230?
Claim 1’s requirement to select an immortalized human blood host cell that produces a protein composition with no detectable NeuGc, α2-6 linked NeuNAc, and ≥15% higher NeuNAc (sialylation degree) versus the same protein expressed in CHOdhfr- [ATCC CRL-9096].

2) Does the patent only cover sialylation?
No. It also targets NeuGc absence, terminal Galα1-3Gal absence (dependent), bisecting GlcNAc, reduced fucose, G2/G0 distribution, and includes antibody-specific functional deltas in claim 6.

3) How does the patent tie glycosylation to proof of infringement?
By writing the claims in quantitative glycan metrics (percent carbohydrate structures, percent shifts in G2/G0, percent uplift in NeuNAc) versus specified comparator cell lines.

4) What is the role of DHFR and methotrexate in this patent?
They appear in dependent claims 8–9 as a required expression/selection mechanism using an antifolate-resistant DHFR variant with antifolate being methotrexate and DHFR variant sequences in SEQ ID 1 to 9.

5) Can a competitor avoid infringement by using different proteins?
Not if their host cell still meets the glycan selection criteria and expression steps for claim 1. The claim list of proteins and antibodies is broad, so avoidance typically focuses on host cell phenotype and host/expression system constraints, not target identity alone.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	January 16, 1978	⤷ Start Trial	2035-05-04
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	October 21, 1942	⤷ Start Trial	2035-05-04
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	March 03, 1954	⤷ Start Trial	2035-05-04
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	July 23, 1976	⤷ Start Trial	2035-05-04
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	August 15, 1978	⤷ Start Trial	2035-05-04
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	November 29, 2022	⤷ Start Trial	2035-05-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,280,230

Summary for Patent: 10,280,230